



Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	February 6, 2013  November 2014, June 3, 2019

## **GATTEX® (teduglutide)**

**LENGTH OF AUTHORIZATION:** Up to one year

### **INITIAL REVIEW CRITERIA:**

- Patient must be  $\geq 1$  year old.
- Patient must have a diagnosis of short bowel syndrome-intestinal failure (SBS-IF)
- Patient must be currently receiving parenteral nutrition or IV fluids on an ongoing basis (Optimization of adjunctive medications and dietary modifications can achieve adequate intestinal rehabilitation in many patients and should be tried prior to initiating teduglutide).

### **REVIEW FOR CONTINUATION OF APPROVAL:**

- Patient is still requiring parenteral nutrition/IV fluids but a reduction in the volume of parenteral support since the implementation of teduglutide therapy **has been achieved** (verified by supporting documentation).
- At this time, there is insufficient clinical information to determine if patients who have successfully been weaned completely off parenteral support need to continue teduglutide therapy.

### **DOSING & ADMINISTRATION:**

- Maximum dose of 0.05 mg/kg/day **subcutaneously** once daily.
- Dosage Form: 5 mg powder for injection to be reconstituted with 0.5 mL sterile water for injection provided in prefilled syringe